MADRID—Researchers say that whole-body MRI could yield an earlier diagnosis of spondyloarthropathy (SpA) in patients with early inflammatory joint symptoms, according to findings presented in a poster session at the Annual European Congress of Rheumatology (EULAR). The approach could lead to earlier treatment and better outcomes, they say. Investigators at the University of Leeds recruited…
Search results for: psoriatic arthritis
Support Rheumatic Disease Awareness Month in September
Wider awareness and understanding of the more than 100 different rheumatic diseases is a vital element in our work as rheumatologists and rheumatology health professionals. Stimulating interest and engagement among lawmakers, patient groups and the public at large is essential to successful advocacy efforts, as well as the overall future of our specialty. This September,…
FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
The FDA has approved adalimumab-adbm, a biosimilar, to treat multiple chronic inflammatory diseases…
Beyond Awareness: August Is Psoriasis Action Month
This month, the National Psoriasis Foundation is urging patients and rheumatologists to take charge of psoriatic disease by setting ambitious treatment goals to achieve better health outcomes…
HSCT for Severe Autoimmune Diseases
Despite the innovations of new biologics and disease-modifying anti-rheumatic drugs, a large unmet need remains for patients with rheumatic autoimmune disease. Treatment remains limited for many conditions, including for conditions with a dim prognosis, such as systemic sclerosis.1 One promising treatment avenue is hematopoietic stem-cell transplantation (HSCT). Here, we provide background on HSCT for severe…
Rheumatology Drug Updates: Opana ER Painkiller Pulled from U.S. Market; Upadacitinib to Treat RA, and More
Opana ER Pulled from U.S. Market Last month, the U.S. Food and Drug Administration (FDA) asked Endo Pharmaceuticals to remove oxymorphone hydrochloride extended release (Opana ER) from the U.S. market due to public health consequences related to abuse. The agency has concerns that the risks presented by the treatment do not outweigh its benefits.1 On…
Gut Microbe, Prevotella copri, Implicated in RA Pathogenesis
New research reinforces the hypothesis that the gut microbiome triggers mucosal and systemic immune responses in patients with rheumatoid arthritis. The research, published in Arthritis & Rheumatology May 2017, found that subgroups of patients with RA have differential immunoglobulin G (IgG) or IgA immune reactivity with Prevotella copri, an intestinal microbe that appears to be…
2 Biosimilars Make Their Way Toward the European Market
Two biosimilar treatments, Rixathon and Imraldi, are moving closer to market release in Europe for the treatment of rheumatic and other diseases…
Amyloidosis Is Often Underdiagnosed, Undertreated
CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…
Predictive Value of Whole-Body MRI & Ultrasound Explored in EULAR Studies
Highlights from the 2017 EULAR Congress MADRID—Researchers say that whole-body MRI could yield an earlier diagnosis of spondyloarthropathy (SpA) in patients with early inflammatory joint symptoms, according to findings presented in a poster session at the Annual European Congress of Rheumatology (EULAR). The approach could lead to earlier treatment and better outcomes, they say. Investigators…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 57
- Next Page »